{"trials":[{"trialNumber":"NRG-GY026","trialType":"GYN Endometrial Neoadjuvant","statusDate":"2026-07-09","title":"NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"Alliance A022101","trialType":"GI Colorectal Advanced","statusDate":"2026-01-13","title":"Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ECOG-ACRIN EA2192","trialType":"GI Pancreatic Adjuvant","statusDate":"2025-12-19","title":"ECOG-ACRIN EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"NRG EAY191-N4","trialType":"GYN Endometrial Advanced","statusDate":"2025-12-15","title":"NRG EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial\r\n","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"NRG-GY025","trialType":"GYN Endometrial Adjuvant","statusDate":"2025-09-19","title":"NRG Oncology NRG-GY025: A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"NRG GU012","trialType":"GU Renal Cell Advanced","statusDate":"2025-09-19","title":"NRG GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"NRG GU012","trialType":"GU Renal Cell Advanced","statusDate":"2025-09-19","title":"NRG GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)","importDate":"2026-07-21","trialSite":"Lovelace Radiation Oncology"},{"trialNumber":"SWOG S2101","trialType":"Solid Tumors Other","statusDate":"2025-09-18","title":"SWOG S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S1931","trialType":"GU RenalCell Adjuvant","statusDate":"2025-09-08","title":"SWOG S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"EA2185","trialType":"GI Other","statusDate":"2025-08-01","title":"EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs ","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S2114","trialType":"Hematology Lymphoma Non-Hodgkins","statusDate":"2025-07-11","title":"SWOG S2114: A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma\n","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"DCP-001","trialType":"Supportive","statusDate":"2025-06-17","title":"DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)","importDate":"2026-07-21","trialSite":"Lovelace Women\u0027s Hospital"},{"trialNumber":"Alliance A012103","trialType":"Breast Other","statusDate":"2025-06-11","title":"Alliance A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy","importDate":"2026-07-21","trialSite":"Presbyterian Medical Group"},{"trialNumber":"Alliance A012103","trialType":"Breast Other","statusDate":"2025-06-11","title":"Alliance A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"Alliance A012103","trialType":"Breast Other","statusDate":"2025-06-11","title":"Alliance A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"Alliance A081801","trialType":"Lung SCLC Adjuvant","statusDate":"2025-06-11","title":"Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"RTOG 1216","trialType":"Head and Neck Advanced","statusDate":"2025-05-01","title":"RTOG 1216: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S2007","trialType":"Breast Advanced","statusDate":"2025-02-21","title":"SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S2007","trialType":"Breast Advanced","statusDate":"2025-02-21","title":"SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"SWOG S2007","trialType":"Breast Advanced","statusDate":"2025-02-21","title":"SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases","importDate":"2026-07-21","trialSite":"Presbyterian Medical Group"},{"trialNumber":"NRG-GY026","trialType":"GYN Endometrial Neoadjuvant","statusDate":"2024-12-10","title":"NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S1501","trialType":"Breast Advanced","statusDate":"2024-11-01","title":"SWOG S1501: Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ECOG-ACRIN EA5182","trialType":"Lung NSCLC Advanced","statusDate":"2024-10-16","title":"ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ECOG-ACRIN EA8134","trialType":"GU Other","statusDate":"2024-09-05","title":"ECOG-ACRIN EA8134: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"NRG-GU010","trialType":"GU Prostate Neoadjuvant","statusDate":"2024-07-01","title":"NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"NRG-GU010","trialType":"GU Prostate Neoadjuvant","statusDate":"2024-07-01","title":"NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)","importDate":"2026-07-21","trialSite":"Lovelace Radiation Oncology"},{"trialNumber":"NRG-GU010","trialType":"GU Prostate Neoadjuvant","statusDate":"2024-06-25","title":"NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)","importDate":"2026-07-21","trialSite":"Presbyterian Medical Group"},{"trialNumber":"NRG-GU010","trialType":"GU Prostate Neoadjuvant","statusDate":"2024-06-25","title":"NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"Alliance A012103","trialType":"Breast Other","statusDate":"2023-11-14","title":"Alliance A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"ECOG-ACRIN EA3161","trialType":"Head and Neck Advanced","statusDate":"2023-10-13","title":"ECOG-ACRIN EA3161: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S2205","trialType":"Supportive","statusDate":"2023-09-26","title":"SWOG S2205: ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Included Peripheral Neuropathy","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ECOG-ACRIN EAY191","trialType":"Advanced Solid Tumors","statusDate":"2023-08-21","title":"ECOG-ACRIN EAY191: Molecular Analysis for Combination Therapy Choice (ComboMATCH)\n","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ALLIANCE A211901","trialType":"Head and Neck Other","statusDate":"2023-03-31","title":"ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ALLIANCE A211901","trialType":"Head and Neck Other","statusDate":"2023-03-31","title":"ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"ASCO TAPUR","trialType":"Advanced Solid Tumors","statusDate":"2023-03-09","title":"ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR™) Study","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"DCP-001","trialType":"Supportive","statusDate":"2023-01-04","title":"DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)","importDate":"2026-07-21","trialSite":"Presbyterian Medical Group"},{"trialNumber":"DCP-001","trialType":"Supportive","statusDate":"2023-01-04","title":"DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"NRG-GI008","trialType":"GI Colorectal Adjuvant","statusDate":"2022-08-19","title":"NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"NRG-GI008","trialType":"GI Colorectal Adjuvant","statusDate":"2022-08-19","title":"NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","importDate":"2026-07-21","trialSite":"Presbyterian Medical Group"},{"trialNumber":"NRG-GI008","trialType":"GI Colorectal Adjuvant","statusDate":"2022-08-19","title":"NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"NRG-GI008","trialType":"GI Colorectal Adjuvant","statusDate":"2022-08-18","title":"NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"INST UNM 2004","trialType":"Breast Adjuvant","statusDate":"2022-05-27","title":"INST UNM 2004: Patient Understanding of the Benefit of Adjuvant Endocrine Therapy in Breast Cancer","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"NRG-GU009","trialType":"GU Other","statusDate":"2022-04-15","title":"NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S2104","trialType":"GI Pancreatic Adjuvant","statusDate":"2022-03-21","title":"SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ASCO TAPUR","trialType":"Advanced Solid Tumors","statusDate":"2021-10-20","title":"ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR™) Study","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ASCO TAPUR","trialType":"Advanced Solid Tumors","statusDate":"2021-10-20","title":"ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR™) Study","importDate":"2026-07-21","trialSite":"Presbyterian Medical Group"},{"trialNumber":"ASCO TAPUR","trialType":"Advanced Solid Tumors","statusDate":"2021-10-20","title":"ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR™) Study","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"ASCO TAPUR","trialType":"Advanced Solid Tumors","statusDate":"2021-10-20","title":"ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR™) Study","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"INST UNM 1903","trialType":"Hematology Other","statusDate":"2021-06-25","title":"INST UNM 1903: Collection of Apheresed Leukocytes for Research and Cell Therapy Process Development\n","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"CIBMTR Protocol for a Research Database","trialType":"Epidemiological","statusDate":"2020-11-10","title":"CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"UNM 1509","trialType":"GYN Other","statusDate":"2020-06-29","title":"INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies\r\n","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG S1703","trialType":"Breast Other","statusDate":"2020-04-28","title":"SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer ","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"SWOG S1703","trialType":"Breast Other","statusDate":"2020-03-02","title":"SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer ","importDate":"2026-07-21","trialSite":"Presbyterian Rust Medical Center"},{"trialNumber":"SWOG S1703","trialType":"Breast Other","statusDate":"2020-03-02","title":"SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer ","importDate":"2026-07-21","trialSite":"Presbyterian Medical Group"},{"trialNumber":"SWOG S1703","trialType":"Breast Other","statusDate":"2020-03-02","title":"SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer ","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"SWOG LungMAP","trialType":"Lung NSCLC Advanced","statusDate":"2019-04-17","title":"SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)","importDate":"2026-07-21","trialSite":"New Mexico Oncology Hematology Consultants"},{"trialNumber":"SWOG LungMAP","trialType":"Lung NSCLC Advanced","statusDate":"2019-03-26","title":"SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"INST LWH 1806","trialType":"Breast Other","statusDate":"2019-03-14","title":"INST LWH 1806: TARGIT New Mexico","importDate":"2026-07-21","trialSite":"Lovelace Radiation Oncology"},{"trialNumber":"INST LWH 1806","trialType":"Breast Other","statusDate":"2019-03-14","title":"INST LWH 1806: TARGIT New Mexico","importDate":"2026-07-21","trialSite":"Lovelace Women\u0027s Hospital"},{"trialNumber":"SWOG LungMAP","trialType":"Lung NSCLC Advanced","statusDate":"2019-03-14","title":"SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"ECOG-ACRIN E4512","trialType":"Lung NSCLC Adjuvant","statusDate":"2019-03-01","title":"ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein","importDate":"2026-07-21","trialSite":"New Mexico Oncology Hematology Consultants"},{"trialNumber":"CCTG MA.39","trialType":"Breast Neoadjuvant","statusDate":"2018-11-05","title":"CCTG MA.39:  A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer","importDate":"2026-07-21","trialSite":"New Mexico Oncology Hematology Consultants"},{"trialNumber":"INST UNM 1512","trialType":"Hematology Acute Leukemia","statusDate":"2018-05-23","title":"INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"INST UNM 1521 - TCCP","trialType":"Epidemiological","statusDate":"2017-12-08","title":"INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer\n","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"CIBMTR Protocol for a Research Database","trialType":"Epidemiological","statusDate":"2017-06-29","title":"CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"DCP-001","trialType":"Supportive","statusDate":"2017-05-24","title":"DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"DCP-001A","trialType":"Supportive","statusDate":"2017-05-24","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"DCP-001B","trialType":"Supportive","statusDate":"2017-05-24","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"DCP-001C","trialType":"Supportive","statusDate":"2017-05-24","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"DCP-001D","trialType":"Supportive","statusDate":"2017-05-24","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Memorial Medical Center"},{"trialNumber":"DCP-001","trialType":"Supportive","statusDate":"2016-08-17","title":"DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"DCP-001A","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"DCP-001B","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"DCP-001C","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"DCP-001D","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Lovelace Medical Center-Saint Joseph Square"},{"trialNumber":"DCP-001A","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Southwest Gynecologic Oncology Associates"},{"trialNumber":"DCP-001B","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Southwest Gynecologic Oncology Associates"},{"trialNumber":"DCP-001C","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Southwest Gynecologic Oncology Associates"},{"trialNumber":"DCP-001D","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"Southwest Gynecologic Oncology Associates"},{"trialNumber":"DCP-001","trialType":"Supportive","statusDate":"2016-08-17","title":"DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"DCP-001A","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"DCP-001B","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"DCP-001C","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"DCP-001D","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-07-21","trialSite":"UNM - CRTC"},{"trialNumber":"LRRI #1054101","trialType":"Lung Ancillary","statusDate":"2001-03-01","title":"LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes","importDate":"2026-07-21","trialSite":"Lovelace Respiratory Research Institute"}]}